Disease
Graft-versus-host disease
Donor T cells recognise host alloantigens → alloresponse.
Also called: GvHD, GVHD, graft versus host disease, acute GvHD, chronic GvHD
In short
- 1What it is: a disease in diseases and immunopathology.
- 2How it connects: acts on 0 and is affected by 3 concepts — mostly 2 cell, 1 therapy.
- 3Where it sits: failure, disease on the 15-step immune chain.
What it does
Ruxolitinib (JAK1/2): REACH-2/3 trials → FDA approved aGVHD and cGVHD; axatilimab (anti-CSF-1R mAb): AGAVE-201 → ORR 74% in 3rd+ line cGVHD (FDA 2024, first drug specifically targeting cGVHD fibrosis biology); PTCy enables haploidentical HSCT (~95% of patients have a haploidentical donor)
Its connections at a glance
Each dot is a concept directly linked to Graft-versus-host disease. Colours show the kind of concept.
Sources & evidenceloading…
Loading reviewed sources…
Graph ID D016 · concept status: established. Select any connection above to inspect evidence for that specific link.